Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H2 2016

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H2 2016


  • Products Id :- GMDHC8907IDB
  • |
  • Pages: 40
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy-Pipeline Review, H2 2016, provides an overview of the Multiple System Atrophy (Central Nervous System) pipeline landscape.

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively.

Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Multiple System Atrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Multiple System Atrophy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Multiple System Atrophy (Central Nervous System)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Multiple System Atrophy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Overview 6

Therapeutics Development 7

Pipeline Products for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Overview 7

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Therapeutics under Development by Companies 8

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Products under Development by Companies 11

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Companies Involved in Therapeutics Development 12

AFFiRiS AG 12

AstraZeneca Plc 13

Corestem Inc 14

MitoDys Therapeutics Ltd 15

Modag GmbH 16

Neuropore Therapies Inc 17

Prana Biotechnology Ltd 18

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

Anle-138b-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

AZD-3241-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

CS-10BR05-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

NPT-20011-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

PBT-434-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

PD-01-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

PD-03-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules for Neurodegenerative Disease-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Appendix 39

Methodology 39

Coverage 39

Secondary Research 39

Primary Research 39

Expert Panel Validation 39

Contact Us 39

Disclaimer 40

List of Figures

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

List of Tables

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by AFFiRiS AG, H2 2016 12

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by AstraZeneca Plc, H2 2016 13

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Corestem Inc, H2 2016 14

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by MitoDys Therapeutics Ltd, H2 2016 15

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Modag GmbH, H2 2016 16

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Neuropore Therapies Inc, H2 2016 17

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Prana Biotechnology Ltd, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AFFiRiS AG, AstraZeneca Plc, Corestem Inc, MitoDys Therapeutics Ltd, Modag GmbH, Neuropore Therapies Inc, Prana Biotechnology Ltd

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Therapeutic Products under Development, Key Players in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Therapeutics, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Overview, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Assessment

select a license

Single User License
USD 2000 INR 129800
Site License
USD 4000 INR 259600
Corporate User License
USD 6000 INR 389400

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com